Diversification of Glomerular Kidney Disease Treatments By Targeting Therapeutics to the Kidney
通过针对肾脏的治疗来实现肾小球肾病治疗的多样化
基本信息
- 批准号:10808617
- 负责人:
- 金额:$ 36.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-22 至 2025-09-14
- 项目状态:未结题
- 来源:
- 关键词:AcuteAnimal ModelAnnexinsBiodistributionCharacteristicsChargeChronicColoradoDepositionDevelopmentDialysis procedureDiseaseDoseDrug Delivery SystemsDrug FormulationsDrug KineticsEnd stage renal failureExhibitsExposure toFormulationGlomerular Mesangial CellGrantGrowth Factor ReceptorsHumanImatinibImmunoglobulin FragmentsImmunosuppressionIn VitroKidneyKidney DiseasesLigandsLinkLocalized DiseaseLupusLupus NephritisMedical centerMorbidity - disease rateMusOilsPDGFRB geneParticle SizePathologyPatientsPharmaceutical PreparationsPharmacodynamicsPlatelet-Derived Growth FactorPlatelet-Derived Growth Factor ReceptorPopulationProcessProteinsPublishingRenal functionRenal glomerular diseaseResearchRiskSafetySchoolsScientistStructureSurvival RateSystemic Lupus ErythematosusTechniquesTestingTherapeuticToxic effectToxicologyTranslatingTreatment EfficacyUniversitiesWaterclinical efficacydrug developmenteffective therapyefficacy evaluationimprovedin vivomesangial cellmortalitymortality riskmouse modelnanoemulsionnanoformulationnovelnovel strategiespre-clinicalreceptorside effectsynergismsystemic toxicitytargeted treatmenttreatment responseuptake
项目摘要
ABSTRACT
Novel approaches to the treatment of glomerular kidney diseases are needed given that they represent the
third most common cause of end stage renal disease. Systemic lupus erythematosus induced kidney disease
(SLEN) is one glomerular disease where up to 60% of patients exhibit significant declines in kidney function,
resulting in end stage renal disease in ~20%. Although novel treatments are being explored for lupus, they
generally do not benefit the majority of patients and cause systemic immunosuppression, leaving the majority
of the population with less effective treatment options. Additionally, neither new nor old treatments have been
evaluated for their ability to target to the kidney and achieve sufficient exposure to influence the localized
disease processes. The development of novel and effective renal targeted treatment approaches for
glomerular kidney diseases, including SLEN, are needed to meet the clinical efficacy and safety needs
of patients with these disorders. We have recently published research for enhanced kidney deposition of
imatinib in a murine model of SLEN, when formulated in a nanoemulsion developed to optimize kidney
exposure. Results from our studies showed three-fold higher kidney deposition of imatinib in MRL/MpJ-Faslpr
mice that received our novel nanoformulation vs. free drug. We will now test the novel imatinib formulation after
chronic dosing to evaluate efficacy and safety in two mouse models of SLEN. We will also modify this
formulation by linking a relevant ligand or an antibody fragment to target a receptor and protein, respectively,
that are upregulated in glomerular mesangial cells in SLEN. We will test whether these formulation
techniques applied to the existing nanoemulsion will enhance imatinib glomerular deposition and
retention, improve selectivity for targeting mesangial cells, improve therapeutic efficacy and provide
relative safety, as compared to our primary formulation. The central hypotheses of our research are that
1) promising SLEN treatments can be formulated to enhance delivery to the diseased kidney and targeted
structures, and 2) animal models that represent human SLEN will demonstrate favorable treatment responses,
pharmacokinetics, and enhanced safety with imatinib nanoformulations vs. free drug. The research team
comprised of scientists with diverse backgrounds in glomerular kidney diseases, drug development,
nanoformulations, toxicology, and renal pathology across schools at the University of Colorado Anschutz
Medical Center, will synergize their efforts to successfully develop novel strategies to enhance kidney delivery
and accumulation of therapeutics for the treatment of glomerular kidney diseases.
摘要
考虑到肾小球肾病代表了肾小球疾病,因此需要治疗肾小球肾病的新方法。
第三大最常见的原因是终末期肾病。系统性红斑狼疮肾病
(SLEN)是一种肾小球疾病,其中高达60%的患者表现出肾功能的显著下降,
导致约20%的终末期肾病。虽然新的治疗方法正在探索狼疮,
通常不会使大多数患者受益,并引起全身免疫抑制,
有效治疗方案较少的人群。此外,无论是新的还是旧的治疗方法,
评价其靶向肾脏并实现足够暴露以影响局部
疾病过程。新型有效的肾脏靶向治疗方法的开发
肾小球肾病,包括SLEN,需要满足临床疗效和安全性需求
这些疾病的患者。我们最近发表了一项研究,
伊马替尼在SLEN小鼠模型中的作用,当配制成纳米乳剂时,
exposure.我们的研究结果显示,MRL/MpJ-Faslpr中伊马替尼的肾脏沉积高出三倍
接受我们的新型纳米制剂与游离药物的小鼠。我们现在将测试新的伊马替尼制剂,
长期给药以评估在两种SLEN小鼠模型中的功效和安全性。我们还将修改此
通过将相关配体或抗体片段分别连接到靶向受体和蛋白质,
在SLEN的肾小球系膜细胞中上调。我们将测试这些配方是否
应用于现有纳米乳剂的技术将增强伊马替尼肾小球沉积,
保留,提高靶向系膜细胞的选择性,提高治疗功效,并提供
相对安全性,与我们的主要配方相比。我们研究的主要假设是,
1)可以配制有前景的SLEN治疗以增强对患病肾脏的递送,
结构,和2)代表人SLEN的动物模型将显示有利的治疗反应,
与游离药物相比,伊马替尼纳米制剂具有更好的药代动力学和更高的安全性。研究团队
由在肾小球肾病,药物开发,
科罗拉多大学安舒茨分校的纳米制剂、毒理学和肾脏病理学
医学中心,将协同努力,成功地开发新的战略,以提高肾脏交付
和积累用于治疗肾小球肾病的治疗剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MELANIE S JOY其他文献
MELANIE S JOY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MELANIE S JOY', 18)}}的其他基金
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease
慢性肾病的药物代谢酶和转运蛋白功能
- 批准号:
8759210 - 财政年份:2014
- 资助金额:
$ 36.79万 - 项目类别:
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease
慢性肾病的药物代谢酶和转运蛋白功能
- 批准号:
9329438 - 财政年份:2014
- 资助金额:
$ 36.79万 - 项目类别:
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease
慢性肾病的药物代谢酶和转运蛋白功能
- 批准号:
9144405 - 财政年份:2014
- 资助金额:
$ 36.79万 - 项目类别:
PHARMACOGENIC REASONS FOR POOR LUPUS NEPHRITIS OUTCOMES
狼疮性肾炎预后不良的药理学原因
- 批准号:
7716807 - 财政年份:2008
- 资助金额:
$ 36.79万 - 项目类别:
P-GLYCOPROTEIN AND CYTOCHROME P450 GENOTYPE AND PHENOTYPE ON RESPONSE TO ANCA
P-糖蛋白和细胞色素 P450 基因型和表型对 ANCA 的反应
- 批准号:
7716797 - 财政年份:2008
- 资助金额:
$ 36.79万 - 项目类别:
P-GLYCOPROTEIN AND CYTOCHROME P450 GENOTYPE AND PHENOTYPE ON RESPONSE TO ANCA
P-糖蛋白和细胞色素 P450 基因型和表型对 ANCA 的反应
- 批准号:
7625574 - 财政年份:2006
- 资助金额:
$ 36.79万 - 项目类别:
PHARMACOGENIC REASONS FOR POOR LUPUS NEPHRITIS OUTCOMES
狼疮性肾炎预后不良的药理学原因
- 批准号:
7625587 - 财政年份:2006
- 资助金额:
$ 36.79万 - 项目类别:
PHARMACOGENIC REASONS FOR POOR LUPUS NEPHRITIS OUTCOMES
狼疮性肾炎预后不良的药理学原因
- 批准号:
7377537 - 财政年份:2005
- 资助金额:
$ 36.79万 - 项目类别:
P-GLYCOPROTEIN AND CYTOCHROME P450 GENOTYPE AND PHENOTYPE ON RESPONSE TO ANCA
P-糖蛋白和细胞色素 P450 基因型和表型对 ANCA 的反应
- 批准号:
7377524 - 财政年份:2005
- 资助金额:
$ 36.79万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 36.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists